Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Capmatinib + Gefitinib in EGFR-mutated c-MET-dysregulated NSCLC
NCT01610336Phase 2Completed
- Sponsor
- Novartis
- Start
- Apr 2012
- Primary completion
- Jun 2016
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Bivalent/Multivalent Binders
- Countries
- 14
01
Overview
Phase 2, open-label trial of capmatinib in non-small cell lung cancer (NSCLC) (11 arms), sponsored by Novartis. Primary endpoints: Dose Limiting Toxicities up to 215 weeks and Overall Response Rate up to 60.8 weeks. Started Apr 2012; status: completed.
02
Drugs
capmatinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT01610336.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01610336.